India's Emcure Pharma rises on Poviztra approval, Motilal initiation with 'buy'

Emcure Pharmaceuticals

21/07/2026 06:55

** Emcure Pharma's shares EMCU.NS rise 2% to 1,898.50 rupees after the drugmaker says Poviztra, its co-marketed brand of innovator semaglutide, will be available in India to treat adults with non-cirrhotic MASH and moderate to advanced liver fibrosis
** Announcement follows India's drugs regulator's approval of Wegovy for the indication 
** EMCU says Poviztra is manufactured and imported from Novo Nordisk's European facility
** Motilal Oswal initiates coverage on Emcure with a "buy" rating and a Street-high price target of 2,260 rupees, implying 27% upside 
** Brokerage expects EMCU's differentiated product pipeline and commercial network to drive revenue and profit CAGRs of 14% and 22%, respectively, over FY26-FY28
** Average rating of six analysts covering the stock is "strong buy," while the median price target is 1,932 rupees, LSEG data shows; Motilal Oswal's initiation is not yet reflected in LSEG 
** EMCU shares are up 38% so far in 2026, outperforming a 14.1% rise in the pharma index .NIPHARM

 (Reporting by Bharath Rajeswaran in Bengaluru)
 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))